昇興股份(002752.SZ):第一期員工持股計劃第一批股票279.7萬股已出售完畢
格隆匯12月7日丨昇興股份(002752.SZ)公佈,公司第一期員工持股計劃第一批股票合計279.7萬股於2021年11月29日至2021年12月6日通過集中競價方式出售,佔公司總股本比例的0.29%。第一批已解鎖股票尚有20股零股受交易規則限制未能賣出,將計入後續股票解鎖後一併處置。至此,本次員工持股計劃第一批股票已出售完畢,後續將進行相應財產清算和分配工作。公司第一期員工持股計劃第一批股票出售嚴格遵守證券交易市場規則以及中國證監會、深圳證券交易所關於信息敏感期不得買賣股票的規定,未利用內幕信息進行交易。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.